| P50 | author | Ming-Sound Tsao | Q47492209 |
| P2093 | author name string | Li Zhang | |
| | Hongming Pan | |
| | Yu-Hui Wang | |
| | Jong Bok Lee | |
| | Dalam Ly | |
| | Junlin Yao | |
| | Nhu-An Pham | |
| | Hyeonjeong Kang | |
| | Dzana Dervovic | |
| | Linan Fang | |
| P2860 | cites work | Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer | Q21089654 |
| | Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 |
| | Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer | Q33418729 |
| | The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFNα production | Q33769011 |
| | Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy | Q33875615 |
| | Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy. | Q34426965 |
| | Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity | Q35216278 |
| | Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans | Q36231084 |
| | Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 |
| | TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. | Q36731174 |
| | Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional | Q37039243 |
| | TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. | Q37663068 |
| | Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma | Q37701514 |
| | Activating natural cytotoxicity receptors of natural killer cells in cancer and infection | Q38082002 |
| | How Do Cytotoxic Lymphocytes Kill Cancer Cells? | Q38633129 |
| | Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors | Q38740566 |
| | Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice | Q39015610 |
| | Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models | Q39056189 |
| | The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells | Q39693972 |
| | Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation | Q40012326 |
| | Antitumor activity of cytokine-induced killer cells against human lung cancer | Q40053361 |
| | Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway | Q40101993 |
| | Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial | Q40692551 |
| | TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells | Q40794623 |
| | IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels | Q40976868 |
| | γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation | Q41057828 |
| | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial | Q44991597 |
| | Understanding and targeting resistance mechanisms in NSCLC. | Q46915997 |
| | Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms | Q47598216 |
| | The biology and management of non-small cell lung cancer | Q49826396 |
| | Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer | Q49959323 |
| | Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. | Q52716912 |
| | The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. | Q54632436 |
| | Working in "NK Mode": Natural Killer Group 2 Member D and Natural Cytotoxicity Receptors in Stress-Surveillance by γδ T Cells | Q55019451 |
| | Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy | Q55090588 |
| | Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. | Q55223108 |
| | Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer. | Q55311835 |
| | Regulatory Dendritic Cells Restrain NK Cell IFN-γ Production through Mechanisms Involving NKp46, IL-10, and MHC Class I–Specific Inhibitory Receptors | Q61625314 |
| | Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression | Q73977252 |
| | Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study | Q86938912 |
| | Immunotherapy in Lung Cancer | Q88897024 |
| | Chimeric Antigen Receptor Therapy | Q89419402 |
| | Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer | Q90928650 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular medicine | Q3523816 |
| P304 | page(s) | 17 | |
| P577 | publication date | 2019-01-22 | |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15 | |
| P478 | volume | 7 | |